Headlands Technologies’s Bristol-Myers Squibb BMY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q4
Sell
-8,332
Closed -$376K 680
2025
Q3
$376K Sell
8,332
-4,445
-35% -$208K 0.03% 421
2025
Q2
$591K Buy
+12,777
New +$627K 0.07% 274
2024
Q4
Sell
-17,423
Closed -$901K 1221
2024
Q3
$901K Sell
17,423
-101,934
-85% -$4.78M 0.1% 216
2024
Q2
$4.96M Buy
+119,357
New +$5.34M 0.53% 37
2024
Q1
Sell
-12,659
Closed -$650K 1259
2023
Q4
$650K Buy
+12,659
New +$664K 0.19% 110
2023
Q1
Sell
-2,878
Closed -$207K 521
2022
Q4
$207K Buy
+2,878
New +$217K 0.16% 146

Other funds holding BMY

Headlands Technologies's BMY Position: Q4 2025 in Review

Headlands Technologies sold out of Bristol-Myers Squibb (BMY) in Q4 2025, closing a stake of 8,332 shares — an estimated $376K sold.

Headlands Technologies first reported a position in BMY in Q4 2022 and held it in 6 quarters. The position peaked at $4.96M in Q2 2024. 2,454 funds tracked by Wall St. Rank hold BMY as of Q4 2025.

  • Headlands Technologies reported no remaining Bristol-Myers Squibb position as of Q4 2025 after selling out during the quarter.
  • Headlands Technologies sold 8,332 Bristol-Myers Squibb shares in Q4 2025, an estimated $376K.
  • Headlands Technologies first reported a position in Bristol-Myers Squibb in Q4 2022 and held it in 6 quarters.
  • Headlands Technologies's Bristol-Myers Squibb position peaked at $4.96M in Q2 2024.
  • 2,454 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q4 2025.

Based on Headlands Technologies's 13F filing for Q4 2025, filed 13 Feb 2026.